Patupilone (epothilone B, EPO906) inhibits growth and metastasis of experimental prostate tumors in vivo.

Abstract

BACKGROUND:

Microtubule agents appear promising for the treatment of prostate cancer. Patupilone (epothilone B), a highly potent non-taxane microtubule stabilizing agent, was evaluated in models of androgen-independent prostate cancer.

METHODS:

Patupilone was administered to athymic mice bearing human prostate cancer xenografts (subcutaneous DU 145 and PC-3M, orthotopic PC-3M).

RESULTS:

One 4 mg/kg patupilone administration produced transient regression of DU 145 tumors, while two weekly administrations of 2.5 mg/kg produced stable disease followed by protracted regression, however with more pronounced body weight loss. Taxol (15 mg/kg every other day) weakly inhibited tumor growth, but with less body weight loss. Patupilone (5 mg/kg) produced protracted growth inhibition of subcutaneous PC-3M tumors, with transient body weight loss. In mice with orthotopic PC-3M tumors, 4 or 5 mg/kg/week patupilone impaired primary tumor growth, abrogated metastases and enhanced survival, with only transient body weight loss.

CONCLUSIONS:

These data suggest that patupilone holds promise for prostate cancer treatment.

• Authors: Terence O'Reilly, Paul Michael John McSheehy, Fritz Wenger, Marc Hattenberger, Melanie Muller, Juliane Vaxelaire, Karl-Heinz Altmann, Markus Wartmann
• Journal: The Prostate (Prostate) Vol. 65 Issue 3 Pg. 231-40 (Nov 01 2005) ISSN: 0270-4137 [Print] United States
• PMID: 15948135 (Publication Type: Journal Article)
• Copyright: Copyright 2005 Wiley-Liss, Inc

Chemical References

• Antineoplastic Agents
• Epothilones
• Paclitaxel
• epothilone B

Topics

• Animals
• Antineoplastic Agents (pharmacology)
• Body Weight (drug effects)
• Cell Line, Tumor
• Epothilones (pharmacology)
• Humans
• Lymphatic Metastasis
• Male
• Mice
• Mice, Inbred BALB C
• Mice, Nude
• Paclitaxel (pharmacology)
• Prostatic Neoplasms (drug therapy, pathology)
• Xenograft Model Antitumor Assays